Literature DB >> 32901308

Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma.

Bas Groot Koerkamp1, Stefan Buettner2, Jaynee J A Vugts3, Marcia P Gaspersz3, Eva Roos4, Lotte C Franken4, Pim B Olthof4, Robert J S Coelen4, Jeroen L A van Vugt3, Tim A Labeur4, Lieke Brouwer5, Marc G H Besselink4, Jan N M IJzermans3, Sarwa Darwish Murad6, Thomas M van Gulik4, Jeroen de Jonge3, Wojciech G Polak3, Olivier R C Busch4, Joris L Erdmann4.   

Abstract

BACKGROUND: Liver transplantation (LT) has been performed in a select group of patients presenting with unresectable or primary sclerosing cholangitis (PSC)-associated perihilar cholangiocarcinoma (pCCA) in the Mayo Clinic with a reported 5-year overall survival (OS) of 53% on intention-to-treat analysis. The objective of this study was to estimate eligibility for LT in a cohort of pCCA patients in two tertiary referral centers.
METHODS: Patients diagnosed with pCCA between 2002 and 2014 were included from two tertiary referral centers in the Netherlands. The selection criteria used by the Mayo Clinic were retrospectively applied to determine the proportion of patients that would have been eligible for LT.
RESULTS: A total of 732 consecutive patients with pCCA were identified, of whom 24 (4%) had PSC-associated pCCA. Overall, 154 patients had resectable disease on imaging and 335 patients were ineligible for LT because of lymph node or distant metastases. An age limit of 70 years led to the exclusion of 50 patients who would otherwise be eligible for LT. After applying the Mayo Clinic criteria, only 34 patients (5%) were potentially eligible for LT. Median survival from diagnosis for these 34 patients was 13 months (95% CI 3-23).
CONCLUSION: Only 5% of all patients presenting with pCCA were potentially eligible for LT under the Mayo criteria. Without transplantation, a median OS of about 1 year was observed.

Entities:  

Mesh:

Year:  2020        PMID: 32901308      PMCID: PMC7892510          DOI: 10.1245/s10434-020-09001-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  46 in total

1.  Conditional survival in patients with unresectable perihilar cholangiocarcinoma.

Authors:  Marcia P Gaspersz; Stefan Buettner; Jeroen L A van Vugt; Eva Roos; Robert J S Coelen; Jaynee Vugts; Eric J Belt; Jeroen de Jonge; Wojciech G Polak; François E J A Willemssen; Thomas M van Gulik; Jan N M IJzermans; Bas Groot Koerkamp
Journal:  HPB (Oxford)       Date:  2017-07-25       Impact factor: 3.647

2.  Aberrant DNA methylation profile in cholangiocarcinoma.

Authors:  Li Huang; Gabriel Frampton; Li-Jian Liang; Sharon Demorrow
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

3.  Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography.

Authors:  Benjamin R Kipp; Emily G Barr Fritcher; Amy C Clayton; Gregory J Gores; Lewis R Roberts; Jun Zhang; Michael J Levy; Kevin C Halling
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

4.  Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram.

Authors:  B Groot Koerkamp; J K Wiggers; M Gonen; A Doussot; P J Allen; M G H Besselink; L H Blumgart; O R C Busch; M I D'Angelica; R P DeMatteo; D J Gouma; T P Kingham; T M van Gulik; W R Jarnagin
Journal:  Ann Oncol       Date:  2015-06-30       Impact factor: 32.976

5.  Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients.

Authors:  Gennaro Nuzzo; Felice Giuliante; Francesco Ardito; Ivo Giovannini; Luca Aldrighetti; Giulio Belli; Fabrizio Bresadola; Fulvio Calise; Raffaele Dalla Valle; Davide F D'Amico; Leandro Gennari; Stefano M Giulini; Alfredo Guglielmi; Elio Jovine; Riccardo Pellicci; Heinrich Pernthaler; Antonio D Pinna; Stefano Puleo; Guido Torzilli; Lorenzo Capussotti; Umberto Cillo; Giorgio Ercolani; Massimo Ferrucci; Laura Mastrangelo; Nazario Portolani; Carlo Pulitanò; Dario Ribero; Andrea Ruzzenente; Vincenzo Scuderi; Bruno Federico
Journal:  Arch Surg       Date:  2012-01

6.  Organ Transplantation in the Face of Donor Shortage - Ethical Implications with a Focus on Liver Allocation.

Authors:  Michael Lauerer; Katharina Kaiser; Eckhard Nagel
Journal:  Visc Med       Date:  2016-06-13

7.  Cholangiocarcinoma complicating primary sclerosing cholangitis.

Authors:  C B Rosen; D M Nagorney; R H Wiesner; R J Coffey; N F LaRusso
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

8.  Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years.

Authors:  Javier F Aduen; Bangarulingam Sujay; Rolland C Dickson; Michael G Heckman; Winston R Hewitt; Wolf H Stapelfeldt; Jeffrey L Steers; Denise M Harnois; David J Kramer
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

9.  Liver transplantation for unresectable perihilar cholangiocarcinoma.

Authors:  Julie K Heimbach; Gregory J Gores; Michael G Haddock; Steven R Alberts; Scott L Nyberg; Michael B Ishitani; Charles B Rosen
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

10.  Low Skeletal Muscle Density Is Associated with Early Death in Patients with Perihilar Cholangiocarcinoma Regardless of Subsequent Treatment.

Authors:  Jeroen L A van Vugt; Marcia P Gaspersz; Jaynee Vugts; Stefan Buettner; Stef Levolger; Ron W F de Bruin; Wojciech G Polak; Jeroen de Jonge; François E J A Willemssen; Bas Groot Koerkamp; Jan N M IJzermans
Journal:  Dig Surg       Date:  2018-02-16       Impact factor: 2.588

View more
  1 in total

Review 1.  Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art.

Authors:  Lynn E Nooijen; Rutger-Jan Swijnenburg; Heinz-Josef Klümpen; Joanne Verheij; Geert Kazemier; Thomas M van Gulik; Joris I Erdmann
Journal:  Visc Med       Date:  2021-01-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.